Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy

Therapy with immune checkpoint inhibitors (ICIs) has improved overall survival and cancer-related morbidity of cancer treatment even in cancer entities with poor prognosis. Since the approval of the first ICI, ipilimumab, for treatment of advanced melanoma by the Food and Drug Administration (FDA) i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Oncol
Main Authors: Möhn, Nora, Mahjoub, Susann, Gutzmer, Ralf, Satzger, Imke, Beutel, Gernot, Ivanyi, Philipp, Golpon, Heiko, Wattjes, Mike P., Stangel, Martin, Skripuletz, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7749779/
https://ncbi.nlm.nih.gov/pubmed/33381178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8865054
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados